Quantcast

Latest Thrombocytopenia Stories

2008-07-01 15:00:54

WOODCLIFF LAKE, N.J., July 1, 2008 /PRNewswire/ -- Eisai Corporation of North America today announced the preliminary efficacy data from a trial initiated in 2002 comparing Dacogen(R) (decitabine) to Best Supportive Care (BSC) in elderly patients with myelodysplastic syndromes (MDS). The data did not demonstrate a statistically significant advantage of Dacogen treatment on median overall survival. However, response rates were similar to those observed in other clinical trials of Dacogen in...

2008-06-26 09:03:12

Trinity Biotech plc (NASDAQ: TRIB) is pleased to announce that it has been appointed by Akers Biosciences, Inc (LSE: AKR) ('ABI'), a leading designer and manufacturer of rapid diagnostic screening and testing products, as a distributor of its unique PIFA Heparin/Platelet Factor-4 Rapid Assay (HPF4) in the USA and German markets. Heparin is the most widely used intravenous anticoagulant, and is commonly used for the prophylaxis and treatment of thromboembolic disease. It also has numerous...

2008-06-20 18:00:39

PHILADELPHIA, Pa. June 20 /PRNewswire-FirstCall/ -- GlaxoSmithKline today announced that the United States Food and Drug Administration has extended the priority review period for PROMACTA(R) (eltrombopag) for the short-term treatment of previously treated patients with chronic idiopathic thrombocytopenic purpura, as they require more time to review the application. The Prescription Drug User Fee action date has been extended to September 19, 2008. On May 30, the Oncology Drugs Advisory...

2008-06-20 18:00:07

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that the U.S. Food and Drug Administration has extended the priority review period for GlaxoSmithKline's (GSK) New Drug Application (NDA) for PROMACTA(R) (eltrombopag) for the short-term treatment of chronic idiopathic thrombocytopenic purpura (ITP). The Prescription Drug User Fee action date has been extended to September 19, 2008. GSK submitted an NDA for PROMACTA in December 2007. In March 2008, the FDA granted the drug...

2008-06-16 09:01:17

Amgen has announced new positive data from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura, a chronic and serious autoimmune disorder characterized by low platelet counts in the blood. The results continue to show that romiplostim increased and sustained platelet counts with extended treatment, and reduced the need for concurrent and rescue immune thrombocytopenic purpura (ITP)...

2008-06-15 06:00:22

Amgen Inc. (NASDAQ: AMGN) today announced updated results from the ongoing, open-label extension study on the long-term safety and efficacy of romiplostim in adult patients with chronic immune thrombocytopenic purpura (ITP), a chronic and serious autoimmune disorder characterized by low platelet counts in the blood. The updated results continue to show that romiplostim increased and sustained platelet counts with extended treatment, and reduced the need for concurrent and rescue ITP...

2008-04-01 03:00:45

By Jason Sheeler, The Dallas Morning News Apr. 1--Loose change is so annoying," I thought, focusing on anything but the present. I lay inert, terrified to move, my body unnaturally reclined at a 45-degree angle in the hospital bed. But my mind raced, keeping pace with the soft-footed ICU nurses attaching sticky pulse-keeping things all over my body. I clamped my eyes shut, every light, noise and heartbeat feeling like a slap to the nickel-size hematoma I woke up with that morning --...

2007-11-28 18:00:00

PHILADELPHIA, Nov. 28 /PRNewswire-USNewswire/ -- Data from Phase II studies published today in the New England Journal of Medicine (NEJM) report that GlaxoSmithKline's (GSK) investigational compound PROMACTA (TM) (eltrombopag) significantly raised platelet levels in patients with thrombocytopenia (low number of platelets in the bloodstream). The studies were conducted in chronic hepatitis C (HCV) (See Note 1)(where thrombocytopenia complicates disease treatment) and chronic idiopathic...

2007-11-28 15:00:37

A U.S.-led international study has discovered a potential new treatment for chronic immune thrombocytopenic purpura, an autoimmune disease. Researchers at New York-Presbyterian Hospital-Weill Cornell Medical Center said there are an estimated 50,000 to 100,000 people in the U.S. diagnosed with ITP, a disease that reduces the number of blood platelets, causing bruises, nosebleeds and possibly life-threatening brain hemorrhages. In the study, the scientists discovered an investigational...

2007-11-11 03:00:07

By Boren, Todd Reyes, Carlos; Montenegro, Raul; Raimer, Karen Abstract Evan's syndrome is a rare hematological condition defined as immune thrombocytopenic purpura and hemolytic anemia. We describe herein a case of Evan's syndrome diagnosed in a term pregnancy that was refractory to primary therapeutic options. We also describe current treatment options in pregnancy and briefly discuss the pathophysiology of Evan's syndrome and perinatal outcome. Keywords: Pregnancy, Evan's syndrome,...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related